Skip to content
Screener

QuidelOrtho Corporation QDEL Proceeds from debt financing, net of issuance costs

Proceeds from debt financing, net of issuance costs at other companies

CTO
Citius Oncology, Inc.CTOR
$589.7K
ROC
Rank One ComputingROC
$5.38M
Flutter Entertainment logo
Flutter EntertainmentFLUT
$406M-93.2%
Solventum logo
SolventumSOLV
$46M
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$100M
Gilead Sciences logo
Gilead SciencesGILD
$0-100%

Other financials

Income statement

See full
Revenue$630.9M+2.8%
Gross profit$272.9M-0.7%
Operating income-$21.8M+87.9%
Net income-$92.9M+63.6%
EPS (diluted)-$1.36+63.9%

Balance sheet

See full
Cash & equivalents$123.4M-18.7%
Total debt$3.4B+3.0%
Total equity$1.8B-36.4%
Total assets$5.7B-10.4%

Cash flow

See full
Operating cash flow-$110.6M
CapEx$25.5M-32.0%
Free cash flow-$136.1M-61.4%

Valuation

See full
Market cap$942.91M-41.3%
Enterprise value$4.25B-11.2%
P/S0.4×-0.2×

Profitability

See full
Gross margin44.6%-2.7pp
Operating margin-30.8%-49.9pp
Net margin-39.2%-168pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-45.9%-94.9pp
Debt / equity1.9×+0.7×
Current ratio1.4×+0.3×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.

The source filing: QuidelOrtho Corporation’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0001906324-26-000033
Line itemSix Months Ended / June 28, 2026Six Months Ended / June 29, 2025
Proceeds from issuance of common stock2.23.1
Short-term borrowings, net(1.0)1.9
Revolving credit facility, net170.0192.0
Proceeds from long-term borrowings112.6
Payments on long-term borrowings(42.0)(72.0)
Payments on finance lease obligation(1.6)
Payments of tax withholdings related to vesting of stock-based awards(2.0)(4.1)
Net cash provided by financing activities238.2120.9

Item 1. Financial Statements (unaudited)

FAQ

What is QuidelOrtho Corporation's proceeds from debt financing, net of issuance costs?
QuidelOrtho Corporation (QDEL) reported proceeds from debt financing, net of issuance costs of $100M in Q2 2026.
What is the long-term trend for QuidelOrtho Corporation's proceeds from debt financing, net of issuance costs?
Over 2 years (2022 to 2025), QuidelOrtho Corporation's proceeds from debt financing, net of issuance costs has grown at a -3.3% compound annual growth rate (CAGR), from $2.73B to $2.56B.
What does proceeds from debt financing, net of issuance costs mean?
Represents the net cash proceeds received from the issuance of long-term debt instruments after accounting for underwriting fees and other issuance expenses. It indicates the company's ability to access long-term capital markets to fund growth or refinance existing obligations.

Ask your AI about QuidelOrtho Corporation's proceeds from debt financing, net of issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude